English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Another XinTech Success Story: D-Pharm Signs Chinese Deal for Epilepsy Drug

May. 30, 2011

The deal, which includes Nhwa’s commitment to conduct full clinical trials in China under FDA protocol, is worth the equivalent of $10s millions in clinical developments costs and includes upfront, milestone and royalty payments as well.
Moreover, this transaction allows D-Pharm to concentrate on its flagship product, the b-99 for the treatment of ischemic stroke (Phase III clinical trial) , while progressing – at the same time and at almost no additional cost – its second pipeline drug candidate.